After Cutting Back And Clinging On, Will Biotech Bounce Back In 2023?

Tough Conditions Will Persist In 2023

 
• By Andrew McConaghie
  
Biotech
Around 85% of companies which IPO'd in 2020 and 2021 are currently below their initial market values, reflecting a harsher environment. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip